The Johns Hopkins University

Kimberly A Noonan

Ivan M Borrello

Drew M Pardoll

Paolo Serafini

Vincenzo Bronte

Valentina Hoyos Velez

In some embodiments, marrow-infiltrating lymphocytes ('MILs') comprising a chimeric antigen receptor ('CAR') are provided. In some aspects, the embodiments relate to a method for making a recombinant MIL, comprising obtaining bone marrow comprising MILs; and transfecting, transforming, or transducing the MILs with a nucleic acid encoding a chimeric antigen receptor. In some aspects, the embodiments relate to a method for treating a condition in a subject, comprising administering to the subject a MIL comprising a CAR.

Marrow infiltrating lymphocytes (MILs) as a source of T-cells for chimeric antigen receptor (CAR) therapy

In some aspects, the invention relates to compositions comprising marrow infiltrating lymphocytes ('MILs'). The MILs may be activated MILs. In some aspects, the invention relates to methods for activating MILs, comprising incubating MILs in an environment comprising less than 21% oxygen. In some aspects, the invention relates to methods for treating cancer in a subject, comprising administering to the subject a composition comprising activated MILs.

Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditions

Various embodiments of the invention relate to compositions comprising marrow infiltrating lymphocytes ('MILs'). The MILs may be activated MILs. Some embodiments relate to methods for activating MILs, comprising incubating MILs in an environment comprising less than 21% oxygen. Some embodiments relate to methods for treating cancer in a subject, comprising administering to the subject a composition comprising activated MILs.

The invention features methods and compositions featuring a PDE5 inhibitor for treating or preventing immunological-mediated disease in a subject.

Growing community of inventors

Baltimore, MD, United States of America

Kimberly A Noonan